Broadway Wealth Solutions Inc. Acquires Shares of 1,396 IQVIA Holdings Inc. (NYSE:IQV)

Broadway Wealth Solutions Inc. bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,396 shares of the medical research company's stock, valued at approximately $274,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. Vanguard Group Inc. raised its holdings in IQVIA by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock valued at $3,956,087,000 after buying an additional 105,504 shares during the period. FMR LLC raised its stake in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after acquiring an additional 804,963 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of IQVIA by 2.5% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock worth $481,380,000 after acquiring an additional 59,426 shares during the last quarter. Cantillon Capital Management LLC boosted its position in shares of IQVIA by 12.3% during the 4th quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company's stock worth $406,018,000 after purchasing an additional 226,017 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on IQV shares. Citigroup dropped their price objective on IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Barclays cut their price target on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a research note on Monday, February 3rd. UBS Group lowered their price objective on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Stephens began coverage on shares of IQVIA in a research note on Friday, December 20th. They set an "overweight" rating and a $250.00 target price on the stock. Finally, JPMorgan Chase & Co. decreased their price target on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and an average target price of $249.05.

IQVIA Stock Performance

IQV traded down $1.77 on Tuesday, reaching $174.53. The company had a trading volume of 326,998 shares, compared to its average volume of 1,464,805. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1 year low of $169.37 and a 1 year high of $252.88. The stock has a market capitalization of $30.77 billion, a PE ratio of 23.27, a P/E/G ratio of 1.99 and a beta of 1.50. The stock has a 50-day moving average price of $192.73 and a 200-day moving average price of $205.61.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.